Endoplasmic reticulum targeting peptide, agonist, preparation method and application
By using endoplasmic reticulum-targeted peptide agonists and taking advantage of endoplasmic reticulum stress and mitochondrial calcium overload, the side effects of traditional calcium overload therapy and the drug resistance of tumor cells are solved, achieving safe and precise tumor cell killing and immune activation, and reshaping the tumor microenvironment.
Patent Information
- Application Number
- CN202510951922.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-07-10
- Publication Date
- 2025-10-14
AI Technical Summary
Existing calcium overload therapy has problems in treating breast cancer, such as decreased blood pH, inflammatory response, and adaptive drug resistance of tumor cells caused by the introduction of exogenous calcium. Traditional treatments such as surgery and chemotherapy are traumatic and have side effects.
Endoplasmic reticulum-targeted peptide agonists, including the KKKAA peptide sequence and dihydrochlorin e6, are used to mediate deep penetration through the cell-penetrating peptide R8, combined with ultrasound irradiation to generate ROS, activate endoplasmic reticulum stress and mitochondrial calcium uptake channels, achieve endogenous calcium overload, and disrupt tumor cell homeostasis through the cathepsin B response sequence, activating the immune response.
It achieves safe and precise endoplasmic reticulum and mitochondrial calcium overload, destroys tumor cell homeostasis, activates immune response, kills tumor cells with multiple effects, reshapes the tumor microenvironment, enhances immune attack, and avoids the side effects of traditional treatments.
Smart Images

Figure CN120774996A_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The present application relates to the field of biological medicine, in particular to endoplasmic reticulum targeting peptide, agonist, preparation method and application. BACKGROUND
[0002] At present, breast cancer has become a disease that needs to be paid attention to. Although traditional treatment methods such as surgical treatment, radiotherapy and chemotherapy have significant effects, they all have certain disadvantages, such as surgical trauma, drug side effects, radiation exposure, etc. Therefore, developing more precise, efficient and low-damage diagnosis and treatment technology has become the common goal of global researchers.
[0003] Studies have shown that interfering with the normal operation of subcellular organelles (such as mitochondria) in cells can trigger tumor cell apoptosis pathways and inhibit tumor growth.
[0004] Calcium overload therapy refers to the imbalance and disorder of calcium balance system in cells caused by a series of reasons. Mitochondria have higher sensitivity to calcium ions, so disturbing the mitochondrial homeostasis through calcium overload is a very potential cancer treatment method. However, the current methods of triggering calcium overload have certain disadvantages and drawbacks. First, the current methods of causing calcium overload often introduce exogenous Ca 2+ containing substances (CaCO3, CaO2, CaP, etc.) into the body. This method has certain risks, that is, the introduction of a large amount of exogenous calcium will inevitably cause the rapid increase of blood Ca 2+ , causing rapid decline of blood pH, body inflammatory response, systemic toxicity and other hazards. Second, since tumor cells contain multiple Ca 2+ channels to regulate the homeostasis of Ca 2+ in cells, if only Ca 2+ is delivered into cells without interfering with the uptake channels of Ca 2+ , the calcium overload may be offset by the adaptability of tumor cells, resulting in ineffective treatment or drug resistance.
[0005] The endoplasmic reticulum is a key subcellular organelle of cells, and the endoplasmic reticulum stores most of the calcium ions in cells, which is the "warehouse" of calcium ions in cells, and is crucial for maintaining calcium ion signals and cell physiological functions in cells. Mitochondria can take up calcium ions from the endoplasmic reticulum through different channels. SUMMARY
[0006] The present application aims to provide endoplasmic reticulum targeting peptide, agonist, preparation method and application, so as to simultaneously activate endoplasmic reticulum over-stress and mitochondrial calcium uptake channels in a safe and controllable manner, and make free Ca 2+It rapidly flows into the mitochondria, achieving endogenous calcium overload; and simultaneously destroys the homeostasis of the endoplasmic reticulum and mitochondria of tumor cells, allowing the two to synergistically induce the cells to initiate the apoptosis program, thereby achieving the purpose of treating the disease.
[0007] To achieve the above-mentioned object, the present invention adopts the following technical solution: the endoplasmic reticulum targeting peptide includes a KKKAA peptide sequence, and the KKKAA peptide sequence is connected to dihydrochlorin e6 and R8 peptides.
[0008] The endoplasmic reticulum targeting peptide of this patent can, under the mediation of cell-penetrating peptide R8, penetrate deeply into the cells across the vascular-interstitial barrier in solid tumors; because it has a KKKAA peptide sequence, it can accurately target the endoplasmic reticulum and can quickly accumulate in the endoplasmic reticulum; after reaching the endoplasmic reticulum, dihydrochlorin e6 can generate reactive oxygen species (ROS) under ultrasound irradiation to trigger the sonodynamic therapy effect. The generated ROS can accurately strike the endoplasmic reticulum at close range, causing strong endoplasmic reticulum stress. When endoplasmic reticulum stress occurs, it can not only initiate the endoplasmic reticulum-related cell apoptosis program, but also force the endoplasmic reticulum to release Ca 2 + , thereby providing endogenous calcium ions.
[0009] To achieve the above-mentioned purpose, the present invention also adopts the following technical scheme: the agonist includes an endoplasmic reticulum targeting peptide, a mitochondrial membrane disrupting sequence and a sequence responsive to cathepsin B, the mitochondrial membrane disrupting sequence is (KLAKLAK)2, the sequence responsive to cathepsin B is GFLG, and the mitochondrial membrane disrupting sequence is connected to the R8 peptide through the sequence responsive to cathepsin B.
[0010] This patented agonist is enriched in tumor tissues through the enhanced permeability and retention effect (EPR) and, mediated by the cell-penetrating peptide R8, penetrates deeply into cells across the vascular-interstitial barrier within solid tumors. Following cellular internalization, the high concentration of cathepsin B within the tumor cells cleaves the GFLG sequence, separating the (KLAKLAK)2 sequence and the endoplasmic reticulum-targeting peptide.
[0011] Then, under the action of the endoplasmic reticulum targeting peptide, strong endoplasmic reticulum stress can be caused. When endoplasmic reticulum stress occurs, it can not only initiate the endoplasmic reticulum-related cell apoptosis program, but also force the endoplasmic reticulum to release Ca 2+ , thereby providing endogenous calcium ions. At the same time, the (KLAKLAK)2 sequence will cause mitochondrial membrane depolarization, thereby opening the mitochondrial MCU, mPTP and other Ca 2+ Uptake channel. In the endoplasmic reticulum and mitochondria, Ca 2+ Driven by high concentration difference, a large amount of Ca 2+It flows into the mitochondria, causing endogenous calcium overload and further damaging the tumor cells.
[0012] Therefore, the agonist of this patent activates the endoplasmic reticulum excessive stress and mitochondrial calcium uptake channel at the same time, making the free Ca 2+ It rapidly flows into the mitochondria, simultaneously destroying the homeostasis of the endoplasmic reticulum and mitochondria of tumor cells, allowing the two to synergistically induce the cells to initiate the apoptosis program.
[0013] In addition to killing tumor cells themselves, the agonist of this patent also causes endoplasmic reticulum stress and mitochondrial endogenous calcium overload to cause damage-related molecular patterns such as calreticulin (CRT) and high-mobility group protein 1 (HMGB-1) to shift to the cell surface, triggering the ICD effect. This effect can activate dendritic cells (DCs) and cytotoxic T lymphocytes (CTLs), thereby achieving an effective connection between innate immunity and adaptive immunity. In addition, mitochondrial DNA (mtDNA) leaked when mitochondrial membrane integrity is damaged can activate the cyclic guanosine monophosphate-adenylate synthetase (cGAS)-stimulator of interferon genes (STING) signaling pathway, further enhancing the body's innate anti-tumor immune surveillance function. In addition, endoplasmic reticulum calcium ion depletion activates store-operated calcium entry (SOCE), leading to the influx of extracellular calcium ions to replenish the calcium ions consumed in the cytoplasm. This not only ensures a continuous source of calcium for sustained calcium-induced cell death, but also repolarizes tumor-associated macrophages (TAMs) from the immunosuppressive M2 type to the immunoactive M1 type, reshaping the tumor microenvironment (TME) to facilitate immune attack.
[0014] In summary, this patented agonist has the following characteristics and effects:
[0015] 1. This patented agonist uses safe, precise, and controllable ultrasound irradiation as a means of initiating treatment to interfere with subcellular homeostasis (endoplasmic reticulum stress + mitochondrial membrane disturbance); calcium ions in the endoplasmic reticulum are introduced into mitochondria to cause endogenous calcium overload, overcoming the problems associated with traditional exogenous calcium overload and the disadvantages of not regulating mitochondrial calcium uptake channels. This agonist can not only achieve endogenous calcium overload, but also regulate mitochondrial calcium uptake channels, thereby facilitating the entry of endogenous calcium ions into mitochondria.
[0016] 2. Multi-effect killing of tumor cells and activation of the body's immunity: This patented agonist can generate a large amount of reactive oxygen species. The generation of a large amount of reactive oxygen species can not only trigger strong endoplasmic reticulum stress and activate endoplasmic reticulum-related apoptosis programs; at the same time, the corresponding mitochondrial calcium overload can also affect the energy metabolism of tumor cells and induce the upregulation of multiple apoptosis-related proteins, thereby killing tumor cells by a dual attack on mitochondria and endoplasmic reticulum.
[0017] In addition, endoplasmic reticulum stress and calcium overload can enhance the antigen presentation function of dendritic cells and the proliferation of cytotoxic T cells, induce the reprogramming of tumor-associated macrophages, activate the host immune system, comprehensively kill tumors, and prevent tumor recurrence and metastasis.
[0018] 3. This patented agonist, in aqueous solution, self-assembles into stable spherical nanoparticles through rapid precipitation during preparation. The highly hydrophobic sonosensitizer, chlorin e6 (Ce6), spontaneously forms the nanoparticle's "core," while the hydrophilic R8 sequence forms the nanoparticle's "shell," driving the self-assembly process.
[0019] This agonist is generated by peptide self-assembly, which well preserves the biological functions of various peptides and can intervene in the physiological functions of multiple target subcellular organelles at once. At the same time, the self-assembly synthesis method avoids complex preparation processes, facilitating clinical translation and industrial production.
[0020] To achieve the above object, the present invention also adopts the following technical solution: a method for preparing an agonist, firstly synthesizing an endoplasmic reticulum targeting peptide;
[0021] Then, the cathepsin B-responsive sequence GFLG was used to connect the ER targeting peptide and the mitochondrial membrane disrupting sequence;
[0022] The mitochondrial membrane disruption sequence is (KLAKLAK)2.
[0023] Therefore, the preparation method of the patented agonist can be used to prepare the agonist.
[0024] To achieve the above object, the present invention also adopts the following technical solution: a method for preparing an agonist, comprising the following steps:
[0025] S1. EMCN polypeptide was synthesized using standard solid-phase peptide synthesis technology. The EMCN polypeptide sequence was (KLAKLAK)2GFLGR8KKKAA;
[0026] S2. Incubating the obtained EMCN polypeptide in DMF containing hydrazine hydrate; then, sequentially adding HOBT, HBTU, and DIEA to the reaction system, using DMF as the solvent;
[0027] S3. Subsequently, dihydrochlorin e6 is added to the above peptide chain and reacted in the dark; after the reaction is completed, the resin is washed with ethanol and dried under vacuum;
[0028] S4. Subsequently, the product was cleaved from the resin using TFA to obtain a crude product; the crude product was precipitated with ice-cold ether and collected by centrifugation.
[0029] Therefore, the preparation of the patented agonist can also be achieved through this preparation method.
[0030] To achieve the above-mentioned purpose, the present invention adopts the following technical solution: application of endoplasmic reticulum targeting peptides in the manufacture of drugs having endoplasmic reticulum stress effects.
[0031] To achieve the above object, the present invention adopts the following technical solution: application of an agonist in the manufacture of a drug capable of introducing calcium ions in the endoplasmic reticulum into mitochondria to cause endogenous calcium overload.
[0032] In addition, the present invention also discloses the following technical solution: application of the agonist in the manufacture of an ICD inducer. The agonist can induce an ICD effect and thus can be used as an ICD inducer.
[0033] In addition, the present invention also discloses the following technical solution: application of the agonist in the manufacture of a photoacoustic imaging agent. The agonist has a photoacoustic imaging effect and can be used to manufacture a photoacoustic imaging agent.
[0034] Preferably, as an improvement, chlorin e6 is linked to the amino group on the side chain of the first lysine in the KKKAA peptide sequence via a covalent bond.
[0035] Preferably, as an improvement, the R8 peptide is linked to the α-amino group of the first lysine in the KKKAA peptide sequence via a peptide bond. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 Schematic diagram of the synthetic route of EMCN.
[0037] Figure 2 Figure 1 is a graph showing the properties of PPN nanoagonists; A is the chemical structure of EMCN; B is the mass spectrum of EMCN; C is the HPLC spectrum of EMCN; D is the 1HNMR spectra of Ce6, EMCN, and peptides; E is the detailed sequence, molecular weight, and HPLC purity of EMCN, PPN-2, and PPN-3; F is the UV-visible absorption spectrum of EMCN, PPN-2, PPN-3, and Ce6; GI is the CAC assay of EMCN, PPN-2, and PPN-3; J is the transmission electron microscopy image and size distribution of EMCN, with a scale bar of 200 μm; K is the diameter and zeta potential of EMCN, PPN-2, and PPN-3, with n=3; L is the diameter of EMCN during the 14-day observation period; M is a schematic diagram of the cleavage of EMCN by cathepsin B, with the results expressed as mean ± standard deviation, with n=3.
[0038] Figure 3 HPLC chromatograms of EMCN before and after incubation with cathepsin B.
[0039] Figure 4Schematic diagram of in vitro reactive oxygen species generation and cell targeting analysis; A is the singlet oxygen (1O2) generation of PBS, Ce6 and EMCN with or without ultrasound detected by electron spin resonance (ESR) spectroscopy; B is the time-dependent DPBF oxidation process of Ce6 generating singlet oxygen under ultrasound irradiation; C is the singlet oxygen generation capacity of different concentrations of EMCN under ultrasound irradiation; D is the evaluation of the reactive oxygen species generation efficiency under different treatment conditions using SOSG detection method (n=3); E and F are the effects of EMCN, PPN-2, PPN-3 and Ce6 on 4T1 cells and HUVE cells Cytotoxicity analysis of Cs (n=5); G is flow cytometry (FCM) analysis of the intracellular uptake efficiency of EMCN after different incubation times; H is confocal laser scanning microscopy (CLSM) images of 4T1 cells after incubation with EMCN for 0, 1, 2, and 4 hours, scale bar, 50 μm; I is CLSM images of 4T1 cells under different treatment conditions, and J is the result of flow cytometry (FCM) detection of intracellular reactive oxygen species probe (DCFH-DA) signals, scale bar, 50 μm; K is quantitative analysis of DCFH fluorescence intensity in 4T1 cells measured by FCM (n=5). All results are expressed as mean ± standard deviation.
[0040] Figure 5 Time-dependent oxidation of Ce6 by DPBF to produce singlet oxygen under ultrasound irradiation.
[0041] Figure 6 Schematic diagram of the relationship between endoplasmic reticulum stress and reprogramming of calcium ions in subcellular organelles; A is a schematic diagram of ultrasound irradiation-induced endoplasmic reticulum stress and opening of mitochondrial calcium transport channels, leading to dual organelle dysfunction and upregulation of cell apoptosis pathways; B is confocal laser scanning microscopy localization images and corresponding quantitative analysis after co-incubation of different nanoagonists with endoplasmic reticulum tracers; C is the Pearson correlation coefficient (PCC) value of the endoplasmic reticulum with EMCN and PPN-2 after co-incubation of 4T1 cells with EMCN and PPN-2, n = 5; D is a Western blot analysis of endoplasmic reticulum stress-specific markers after different treatments; E is a confocal laser scanning microscopy image of 4T1 cells stained with JC-1 after different treatments, and F is a flow cytometry analysis, the scale bar is 50 μm; G is a confocal laser scanning microscopy image of cells stained with mPTP after different treatments, the scale bar is 25 μm; H is a confocal laser scanning microscopy image of mitochondrial calcium uniporter (MCU) expression in 4T1 cells after different treatments; I is a confocal laser scanning microscopy image of mitochondrial Ca2+ expression in 4T1 cells after different treatments. 2+ Horizontal confocal laser scanning microscopy images; J is the intracellular Ca 2+Horizontal confocal laser scanning microscopy images; K is Western blot analysis of BCL-2, BAX, and cleaved caspase-3 in 4T1 cells after different treatments; L is ultrastructural changes in 4T1 cells after different treatments (observed by transmission electron microscopy), red arrows indicate mitochondria, green arrows indicate endoplasmic reticulum, and the scale bar is 1 μm.
[0042] Figure 7 Schematic diagram of the in vitro anti-tumor efficacy and immune response of EMCN; A is the cell viability of 4T1 cells after different treatments; B is the corresponding quantitative analysis of cell apoptosis; C is the cell apoptosis analysis of 4T1 cells after different treatments; D is the lipid peroxidation level of 4T1 cells stained with BODIPY-C11 after different treatments observed by CLAM, scale bar is 50 μm; E is the Calcein level of 4T1 cells after different treatments AM / PI staining, scale bar, 100 μm; F and G are immunofluorescence images of CRT-exposed (F) and HMGB1-exposed (G) 4T1 cells after different treatments, scale bar, 50 μm; H is an 8-OH-dG image of 4T1 cells after different treatments, scale bar, 50 μm; I is a schematic diagram of the Transwell system experiment; J is flow cytometry analysis of DC maturation in different groups; K is the corresponding quantitative analysis of DC maturation in different groups; L is flow cytometric analysis of CD86 (M1 macrophage marker) and CD206 (M2 macrophage marker) expression in different groups; M and N are the corresponding quantitative analysis; OR is ELISA analysis of IL-6 (O), TNF-α (P), IL-10 (Q), and IL-12 (R) secretion levels. In the figure, G1, control group; G2, ultrasound-only group; G3: Ce6 + US; G4: PPN-3 + US; G5: PPN-2 + US; G6: EMCN + US. The results are expressed as mean ± standard deviation, n = 5.
[0043] Figure 8Figures show the in vivo biodistribution and PAI imaging studies of EMCN nanoparticle agonists. A shows in vivo fluorescence images of 4T1 tumor-bearing mice at different time points after intravenous injection of DIR-loaded EMCN. B shows quantitative analysis of fluorescence intensity at the tumor site in vivo (n = 5). C shows in vitro fluorescence imaging of tumors and major organs, including the heart, liver, spleen, lungs, and kidneys, removed from mice 72 hours later. D shows quantitative analysis of fluorescence intensity of tumors and major organs (n = 5). E shows in vitro PAI images and signal intensity values of tP@TFP NPs at different concentrations (n = 3). F shows a full spectrum scan of EMCN in a photoacoustic system. G shows quantitative analysis of PAI intensity of tumors at different time points after intravenous injection of EMCN (n = 3). H shows PAI images of tumors at different time points after intravenous injection of EMCN. I shows fluorescence intensity of blood samples. J shows the half-life of EMCN. Results are presented as mean ± standard deviation.
[0044] Figure 9 Figures related to the in vivo anti-tumor evaluation study of EMCN; A is a schematic diagram of the treatment regimen for 4T1 tumor-bearing mice; B is the tumor weight after different treatments and C is the tumor inhibition rate; D is the weight change of 4T1 tumor-bearing mice after different treatments; E is a digital photograph of tumors in different treatment groups, n=5; F is the growth curve of individual tumors after different treatments; G is a representative image of H&E staining, TUNEL and PCNA immunofluorescence staining after different treatments, scale bar is 50μM; H is principal component analysis based on differentially expressed proteins between the control group and the EMCN+US group; I is the KEGG pathway of differentially expressed genes; J is a volcano plot of differentially expressed genes in osteosarcoma cells treated with PBS or EMCN+US; K is a heat map of upregulated apoptosis in 4T1 tumor tissues after EMCN+US or saline treatment; L is Western blot detection and (M) quantitative analysis of the expression of PERK, CHOP, BCL-2, BAX and cleaved caspase-3 in 4T1 tumor tissues after different treatments. In the figure, G1, control; G2, ultrasound only; G3, Ce6+ultrasound; G4, PPN-3+ultrasound; G5, PPN-2+ultrasound; G6, EMCN+ultrasound.
[0045] Figure 10Verification of related pictures for remodeling of immunosuppressive tumor microenvironment by PPN nanostimulators; wherein, A is a schematic diagram of EMCN remodeling of immunosuppressive microenvironment mechanism; B is immunofluorescence staining of CRT in tumor site, C is immunofluorescence staining of HMGB1 in tumor site, the scale is 50 microns; D is the proportion of mature dendritic cells (CD80+CD86+ in CD11c+ cells) in draining lymph nodes analyzed by flow cytometry; E is quantitative analysis of mature dendritic cells in draining lymph nodes, F is quantitative analysis of mature dendritic cells in tumor; G is quantitative analysis of M1 macrophages, H is quantitative analysis of M2 macrophages; I is quantitative analysis of CD8+ T cells; J is the proportion of mature dendritic cells (CD80+CD86+ in CD11c+ cells) in tumor analyzed by flow cytometry; K is representative flow cytometry analysis of M1 (CD86+) and M2 (CD206+) macrophages (gated CD11b+F4 / 80+) in tumor; L is representative flow cytometry analysis of CD8+ T cells (gated CD3+) in tumor; M is a picture of lung tissue stained with Bouin's solution and its corresponding H&E staining image, the scale is 2 millimeters. The results are expressed as mean ± standard deviation, n = 5.
[0046] Figure 11 The levels of IFN-γ, TNF-α and IL-6 in the serum of 4T1 mice after different treatments. (G1: control group; G2: ultrasound only; G3: Ce6+ultrasound; G4: PPN-3+ultrasound; G5: PPN-2+ultrasound; G6: EMCN+ultrasound). Data are expressed as mean ± standard deviation, n = 5. DETAILED DESCRIPTION
[0047] The following will be further described in detail through specific embodiments:
[0048] Example 1
[0049] This embodiment discloses an endoplasmic reticulum targeting peptide, which comprises a KKKAA peptide sequence, and a dihydrophenophoe e6 and an R8 peptide connected to the KKKAA peptide sequence. Specifically, the dihydrophenophoe e6 is connected to the amino group on the side chain of the first lysine in the KKKAA peptide sequence through a covalent bond. The R8 peptide is connected to the α-amino group of the first lysine in the KKKAA peptide sequence through a peptide bond.
[0050] This embodiment discloses a stimulator, which comprises the above-mentioned endoplasmic reticulum targeting peptide, and further comprises a mitochondrial membrane disturbing sequence and a sequence with cathepsin B response, the mitochondrial membrane disturbing sequence is (KLAKLAK)2, and the sequence with cathepsin B response is GFLG, the mitochondrial membrane disturbing sequence is connected to the R8 peptide through the sequence with cathepsin B response.
[0051] Example 2
[0052] This example discloses the preparation method of the agonist in Example 1 (refer to Figure 1 and Figure 2 A), comprising the following steps:
[0053] S1. EMCN polypeptide was synthesized using standard solid-phase peptide synthesis technology. The EMCN polypeptide sequence was (KLAKLAK)2GFLGR8KKKAA;
[0054] The specific steps of the standard solid-phase peptide synthesis technology in this step include: A. weighing 2.0g of blank Wang resin into a clean and dry reaction tube, adding 15mL of N,N-dimethylformamide (DMF), and activating at room temperature for about 30min; B. filtering the solvent from the previous step through a sand core at room temperature, adding 1mmol 5-fold molar excess of the first amino acid at the C-terminus, 5-fold molar excess of 4-dimethylaminopyridine DMAP, 5-fold molar excess of N,N'-diisopropylcarbodiimide DIC, N,N-dimethylformamide DMF as solvent and react at room temperature for 3h; C. Add pyridine (5-10mL) and acetic anhydride with a volume ratio of 1:1 and react for 30min; D. Filter off the solvent from the previous step, add 10mL of N,N-dimethylformamide DMF solution containing 20% piperidine to the resin, stir with N2 for 10min, filter out the solution, add 10mL of N,N-dimethylformamide DMF solution containing 20% piperidine, blow and stir with N2 for 5min and filter out the solution; E. Take out a small amount of resin F. Weigh a 3-fold molar excess of the second amino acid at the C-terminus, a 3-fold molar excess of O-benzotriazole-tetramethyluronium hexafluorophosphate HBTU and a 3-fold molar excess of 1-hydroxybenzotriazole HOBT in a reaction tube, add 5-10 mL of N, N-dimethylformamide DMF solution to completely dissolve it, then add a 10-fold molar excess of pure N, N-diisopropylethyl DIEA and react at room temperature for 40 minutes; take a small amount of resin and detect it with ninhydrin detection reagent, it will be colorless, then add 10 mL 20% piperidine DMF solution to remove Fmoc; G. Repeat the above steps until the last amino acid at the N-terminus is synthesized, the last amino acid is Fmoc-Lys(Dde)-OH containing a Dde protecting group, remove the Fmoc protecting group, and then drain;
[0055] S2. The resulting molar excess of EMCN polypeptide is placed in DMF containing hydrazine hydrate (2% hydrazine hydrate dissolved in DMF, or DCM as a solvent in other embodiments) and incubated for 15 minutes to remove the Dde protecting group on lysine. Subsequently, 1 g of HOBT, 0.2 g of HBTU, and 1 ml of DIEA are sequentially added to the reaction system, using DMF as the solvent.
[0056] S3. Subsequently, a molar excess of chlorin e6 (Ce6) was added to the above peptide chain and reacted in the dark for 2 h. After the reaction was completed (the reaction progress was monitored using a ninhydrin reagent; if the resin was colorless, it indicated that Ce6 had completely participated in the reaction), the resin was thoroughly washed with ethanol and dried under vacuum.
[0057] S4. Subsequently, the product is cleaved from the resin using TFA to obtain a crude product, specifically: cutting with a trifluoroacetic acid cutting solution containing 95% trifluoroacetic acid TFA, 2% triisopropylsilane TIS, 2% ethanedithiol EDT and 1% H2O for 2 hours, filtering the reaction solution to obtain a trifluoroacetic acid solution of the peptide functionalized complex; the crude product is precipitated with ice-cold ether and collected by centrifugation, specifically: the trifluoroacetic acid solution is blown dry as much as possible with N2, then precipitated with ether, centrifuged, and then washed with ether 3-5 times to obtain the peptide functionalized complex.
[0058] Finally, the final product was obtained by freeze-drying and purified by high performance liquid chromatography.
[0059] This agonist is defined in this patent as an EMCN agonist.
[0060] Example 3
[0061] This example provides a preparation method different from that of Example 2, but can also prepare an agonist with the same structure.
[0062] Specifically, the agonist preparation method includes first synthesizing an endoplasmic reticulum targeting peptide;
[0063] The endoplasmic reticulum targeting peptide and the mitochondrial membrane disrupting sequence are then connected using the cathepsin B-responsive sequence GFLG; the mitochondrial membrane disrupting sequence is (KLAKLAK)2.
[0064] The endoplasmic reticulum targeting peptide is synthesized by solid phase peptide synthesis method, and the specific method comprises the following steps: A, 2.0 g of blank Wang resin is weighed in a clean and dry reaction tube, 15 mL of N,N-dimethylformamide DMF is added, and the resin is activated at room temperature for about 30 min; B, at room temperature, the solvent in the previous step is filtered out by suction through a sand core, 1 mmol of 5-fold molar excess of the first amino acid at the C-terminal, 5-fold molar excess of 4-dimethylaminopyridine DMAP, and 5-fold molar excess of N,N'-diisopropyl carbodiimide DIC are added, N,N-dimethylformamide DMF is used as a solvent, and reaction is carried out at room temperature for 3 h; C, pyridine (5-10 mL) and acetic anhydride in a volume ratio of 1:1 are added, and reaction is carried out for 30 min; D, the solvent in the previous step is filtered out by suction, 10 mL of N,N-dimethylformamide DMF solution containing 20% piperidine is added to the resin, the solution is filtered out after N2 stirring for 10 min, 10 mL of N,N-dimethylformamide DMF solution containing 20% piperidine is added again, and the solution is filtered out after N2 blowing and stirring for 5 min; E, a small amount of resin is taken out, washed with methanol for 3 times, and one drop of indanetrione, potassium cyanide KCN and phenol solution is added, and heating is carried out at 105-110 DEG C for 5 min; if the resin turns dark blue, it is positive reaction, which indicates that the removal is complete; F, 3-fold molar excess of the second amino acid at the C-terminal, 3-fold molar excess of O-benzotriazole-tetramethyluronium hexafluorophosphate HBTU and 3-fold molar excess of 1-hydroxybenzotriazole HOBT are weighed in the reaction tube, 5-10 mL of N,N-dimethylformamide DMF solution is added to completely dissolve them, and then 10-fold molar excess of pure N,N-diisopropyl ethyl DIEA is added, and reaction is carried out at room temperature for 40 min; a small amount of resin is taken out and detected by using indanetrione detection reagent, and no color is shown, and then 10 mL of 20% piperidine DMF solution is added to remove Fmoc; G, the above steps are repeated until the last amino acid at the N-terminal is synthesized, and the last amino acid is Fmoc-Lys(Dde)-OH containing a Dde protecting group; the Fmoc protecting group is removed, and then the resin is dried by suction to obtain the peptide; H, the obtained peptide is placed in DMF containing hydrazine hydrate (2% hydrazine hydrate is dissolved in DMF solvent) for incubation for 15 min, so as to remove the Dde protecting group on the lysine; I, a molar excess of Ce6 molecules, HOBT 1 g, HBUT 0.2 g and 1 mL of DIEA are added, DMF solvent is added, and attention is paid to avoid light; after reaction for 2 h, indanetrione is monitored, and if the resin is colorless, it indicates that the dye is completely reacted; J, finally, the peptide functionalized complex is obtained by using a trifluoroacetic acid cutting solution containing 95% trifluoroacetic acid TFA, 2% triisopropylsilane TIS, 2% ethanedithiol EDT and 1% H2O for cutting for 2 h, and the reaction solution is filtered by suction to obtain a trifluoroacetic acid solution of the peptide functionalized complex; K, the trifluoroacetic acid solution is dried by N2 as much as possible, and then precipitated by using ether, centrifuged, and then washed with ether for 3-5 times to obtain the peptide functionalized complex.
[0065] Then the cathepsin B response peptide is connected with the endoplasmic reticulum targeting peptide, and the specific method comprises the following steps:
[0066] A, to the cathepsin B responsive peptide is added a molar excess of endoplasmic reticulum targeting peptide molecules, HOBT 1g, HBUT 0.2g, DIEA is 1ml, add DMF solvent, pay attention to avoid light, after 2 hours of reaction, ninhydrin monitoring, the resin is colorless, which indicates that the dye is completely reacted; B, using a trifluoroacetic acid cleavage solution containing 95% trifluoroacetic acid TFA, 2% triisopropylsilane TIS, 2% ethanedithiol EDT and 1% H2O to cut 2h, the reaction solution is extracted by suction filtration, and a trifluoroacetic acid solution of the peptide functionalized complex is obtained; C, the trifluoroacetic acid solution in B is blown dry with N2 as much as possible, then precipitated with ether, centrifuged, and then washed with ether for 3-5 times to obtain the peptide functionalized complex.
[0067] Finally, the mitochondrial membrane disturbing peptide is coupled with the cathepsin B responsive peptide-endoplasmic reticulum targeting peptide-Ce6 complex, and the specific method comprises the following steps:
[0068] A, to the cathepsin B responsive peptide is added a molar excess of endoplasmic reticulum targeting peptide molecules, HOBT 1g, HBUT 0.2g, DIEA is 1ml, add DMF solvent, pay attention to avoid light, after 2 hours of reaction, ninhydrin monitoring, the resin is colorless, which indicates that the dye is completely reacted; B, using a trifluoroacetic acid cleavage solution containing 95% trifluoroacetic acid TFA, 2% triisopropylsilane TIS, 2% ethanedithiol EDT and 1% H2O to cut 2h, the reaction solution is extracted by suction filtration, and a trifluoroacetic acid solution of the peptide functionalized complex is obtained; C, the trifluoroacetic acid solution in B is blown dry with N2 as much as possible, then precipitated with ether, centrifuged, and then washed with ether for 3-5 times to obtain the peptide functionalized complex.
[0069] Example 4
[0070] The endoplasmic reticulum targeting peptide in Example 1 can be applied to the manufacture of a drug having an endoplasmic reticulum stress effect.
[0071] The agonist in Example 1-Example 3 can be applied to the manufacture of a drug having the function of introducing calcium ions in the endoplasmic reticulum into mitochondria to cause endogenous calcium overload, or the manufacture of an ICD inducer, or the manufacture of a photoacoustic imaging agent.
[0072] The effects of the endoplasmic reticulum targeting peptide, the agonist and the application thereof in the present patent are experimentally demonstrated through a series of experiments.
[0073] During the experiment, two agonists, PPN-2 and PPN-3, were prepared as comparisons according to a similar preparation method to the above agonists. Among them, PPN-2 is an agonist that does not contain an endoplasmic reticulum targeting sequence (KKKAA peptide sequence), and the sequence of PPN-2 is: (KLAKLAK)2GFLGR8ORN(Ce6)DDAA. PPN-3 is an agonist that does not contain a mitochondrial membrane perturbation sequence ((KLAKLAK)2), and the sequence of PPN-3 is: (KLGKKLG)2GFLGR8K(Ce6)KKAA. The peptide sequences of these three agonists are detailed in Figure 2 E.
[0074] Experiment 1: Characterization of agonist properties
[0075] The EMCN agonist prepared in Example 2 was analyzed by high-resolution mass spectrometry (HRMS) and the molecular weight of EMCN was consistent with the theoretical value (see Figure 2 B). The purity of the EMCN agonist was further confirmed by high performance liquid chromatography (HPLC) analysis, and the results showed that the purity of EMCN was as high as 95.67% (see Figure 2 C). In addition, the characteristic peaks of EMCN were analyzed by proton nuclear magnetic resonance spectroscopy (NMR) and compared with those of naked peptide and Ce6. The results showed that the peptide and Ce6 had successfully bound (see Figure 2 D).
[0076] To further observe the self-assembly behavior of each nanosystem, the critical aggregation concentration (CAC) was measured using Nile Red (NR) probe. The calculated results showed that the CAC values of EMCN, PPN-2, and PPN-3 were 3.90, 3.01, and 4.19 μM, respectively (see Figure 2 G- Figure 2 I). Transmission electron microscopy (TEM) images showed that EMCN, PPN-2, and PPN-3 all exhibited similar circular nanostructures (see Figure 2 J).
[0077] Dynamic light scattering (DLS) measurements showed that the average particle sizes of EMCN, PPN-2, and PPN-3 were 182.37 ± 2.48, 159.67 ± 6.98, and 164.8 ± 3.77 nm, respectively. Zeta potential measurements showed that the zeta potentials of EMCN, PPN-2, and PPN-3 were 27.45 ± 1.67, 22.95 ± 1.6, and 20.49 ± 0.77 mV, respectively (see Figure 2 K).
[0078] In particular, the hydrodynamic diameter of the EMCN did not change significantly over 14 days (see Figure 2L), and no obvious difference was observed in different solutions, which indicated that it had excellent stability.
[0079] Cathepsin B is a lysosomal protease overexpressed in a variety of tumors, which can specifically cleave substrates containing glycine-phenylalanine-leucine-glycine (GFLG) sequences. The agonist of the present patent can cleave the GFLG sequence by taking advantage of the high concentration of cathepsin B in the tumor microenvironment, thereby separating the cationic motif (KLAKLAK) from the K(Ce6)KKAA motif (see Figure 2 M) High-performance liquid chromatogram (see Figure 3 ) shows that after co-incubation with cathepsin B, the initial peak intensity of EMCN is weakened, indicating that cathepsin B successfully induced peptide chain disintegration.
[0080] Experiment 2: Verification of the active oxygen (ROS) generation ability of the agonist
[0081] First, before carrying out cell experiments, the biological safety of free Ce6 and three kinds of peptide-programmed nano-agonists at different concentrations (0, 1.25, 2.5, 5, 10, and 20 μM, respectively) was evaluated by a cell counting kit 8 (CCK-8). Without ultrasound irradiation, when the concentration reached 20 μM, the survival rates of 4T1 cells treated with Ce6, EMCN, PPN-2, and PPN-3 were all higher than 80% ( Figure 4 E). In addition, the toxicity of these to human umbilical vein endothelial cells (HUVECs) was negligible ( Figure 4 F).
[0082] Then the endocytosis behavior of the nano-agonist was evaluated, and the uptake of EMCN by 4T1 cells (1×10 5 ) was detected by confocal laser scanning microscopy (CLSM) and flow cytometry (FCM) (1 ml, 10 μm). With the extension of incubation time (0.5, 1, 2, and 4 hours), it was observed that the red fluorescence signal of EMCN (indicating the uptake of EMCN by cells) increased with the increase of incubation time (see Figure 4 H). In addition, the results of flow cytometry (FCM) showed that the fluorescence intensity increased significantly with the increase of incubation time, which was consistent with the analysis results of confocal laser scanning microscopy (CLSM) Figure 4 G).
[0083] Then the active oxygen (ROS) generation ability of EMCN was verified by electron spin resonance (ESR) technology, and 2,2,6,6-tetramethylpiperidine (TEMP) was used as a singlet oxygen trapping agent. As Figure 4As shown in Figure A, the experiment was divided into 6 groups to test the singlet oxygen (1O2) generation of PBS, Ce6, and EMCN with or without ultrasound. In this experiment, the concentrations of Ce6 and EMCN used were both 10 μM, and the ultrasound irradiation conditions were: 1 MHz, 1.0 W / cm 2 , 50% duty cycle, irradiation for 4 minutes. The sample volume was 180 μL. Specifically, using PBS buffer as the solvent, a 10 mM xanthine solution and a 1 U / ml xanthine oxidase solution were prepared. 100 μL of xanthine solution and 100 μL of xanthine oxidase solution were added, followed by 20 μL of DMPO and 180 μL of buffer. After incubation for 10 minutes, samples were taken for testing. For the sample test group, the 180 μL buffer was replaced with 180 μL of sample solution. Under the same experimental conditions, both free Ce6 and EMCN exhibited the strongest triplet signals, with a signal intensity ratio of "1:1:1". However, no similar strong characteristic signals were observed when phosphate buffer (PBS) was subjected to ultrasonic irradiation under the same conditions, or in PBS, free Ce6, and EMCN solutions without ultrasonic irradiation.
[0084] In addition, 1,3-diphenylisobenzofuran (DPBF) was used to further determine the generation of ROS. The results showed that under the same power of ultrasound irradiation, the characteristic absorption of free Ce6 and EMCN at 410 nm decreased significantly with the extension of ultrasound irradiation time (see Figure 4 B, Figure 5 In addition, the SOSG probe was used to demonstrate that as the concentration of EMCN (or Ce6) increased, the production of ROS also increased ( Figure 4 C and Figure 4 D).
[0085] Then, the generation of intracellular reactive oxygen species (ROS) was further studied. The intracellular ROS level was detected by 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA) probe. CLSM showed that the green fluorescence in the cells of the PBS group, the simple ultrasound group, the Ce6 group, and the EMCN group was almost invisible, while the Ce6+ultrasound group showed a moderate intensity of fluorescence. In contrast, the 4T1 cells treated with EMCN+ultrasound showed a significantly higher green fluorescence intensity ( Figure 4 I). Meanwhile, the flow cytometry (FCM) analysis results were consistent with the above CLSM results ( Figure 4 J and Figure 4 K). These results indicate that EMCN can efficiently generate ROS under ultrasound irradiation conditions.
[0086] Experiment 3: Endoplasmic reticulum stress verification
[0087] First, the potential targeting ability of EMCN to the endoplasmic reticulum was evaluated. EMCN nanoagonists and PPN-2 agonists were co-incubated with endoplasmic reticulum tracers (4T1 cells were seeded into confocal cell culture dishes and cultured for 24 hours (1×10 per dish)). 5 4T1 cells were then incubated with medium containing PPN-2 or EMCN (both at 10 μM) for 4 hours. After incubation, cells were stained with ER-Tracker Green and DAPI for confocal laser scanning microscopy (CLSM) observation, and colocalization analysis was performed using ImageJ software. Figure 6 As shown in Figure B, the results show that the green fluorescence signal from the ER tracer and the red fluorescence signal from EMCN exhibit good colocalization, and the degree of overlap is significantly higher than that of PPN-2 (without the ER targeting sequence). The average Pearson colocalization coefficients (PCC) of EMCN and PPN-2 with the ER were calculated to be 0.874 and 0.588, respectively. Figure 6 C). This demonstrates that EMCN agonists have excellent ER-targeting capabilities, which helps overcome the limited diffusion distance and half-life of reactive oxygen species (ROS), enabling precise ROS attacks on the ER and further inducing ER stress.
[0088] In addition, endoplasmic reticulum stress-related proteins were evaluated by Western blotting. The experiment was divided into three groups: control group, PPN-2 agonist + ultrasound group, and EMCN agonist + ultrasound group. PPN-2 or EMCN were both 20 μM, and the ultrasound parameters were 1 MHz, 1.0 W / cm 2 ,50% duty cycle, irradiation for 4 minutes; Figure 6 As shown in Figure D, the expression level of the ER stress protein PERK was significantly increased in the EMCN+US group compared with the PPN-2+US group and the control group. Furthermore, the expression of the ER stress-induced pro-apoptotic proteins ATF4, CHOP, and caspase-12 was also significantly upregulated. In contrast, these proteins were only mildly upregulated in the PPN-2+US group, owing to the weak ER stress induced by PPN-2. These results suggest that ROS generated by EMCN under ultrasound irradiation can induce strong ER stress and initiate ER-associated apoptosis.
[0089] Experiment 4: Verification of mitochondrial calcium overload
[0090] Mitochondrial changes in 4T1 cells under different treatment conditions were evaluated using a mitochondrial membrane potential probe (JC-1). The experiment was divided into six groups: control group, ultrasound-only group, PPN-3-only group, EMCN-only group, PPN-3+ultrasound group, and ENCN+ultrasound group. PPN-3 or EMCN were both 20 μM in 1 ml of solution, and the ultrasound parameters were 1 MHz, 1.0 W / cm 2 , 50% duty cycle, irradiation for 4 minutes. The results of confocal laser scanning microscopy (CLSM) and flow cytometry (FCM) showed that the control group, the simple ultrasound group and the PPN-3 group all showed obvious red fluorescence, indicating that the mitochondrial membrane potential (MMP) was not affected. However, the cells in the PPN-3+ultrasound group emitted moderate green fluorescence, indicating that the membrane potential was reduced. It is worth noting that the EMCN+ultrasound-treated cells emitted bright green fluorescence and weak red fluorescence (see Figure 6 E. Figure 6 (F) These results indicate that mitochondrial function is significantly impaired. EMCN-treated cells without ultrasound also exhibited relatively low MMP, likely due to the KLAKLAK sequence disrupting the negative charge on the mitochondrial membrane, leading to reduced MMP.
[0091] Then, the inventors detected the open state of MCU and mPTP. Calcein AM can passively diffuse into cells and accumulate in mitochondria. Cobalt chloride (CoCl2) can quench the green fluorescence of Calcein AM in cells. However, under normal circumstances, the membrane potential pore (mPTP) of mitochondria remains closed, preventing cobalt chloride from entering the mitochondria. Therefore, the degree of openness of mPTP in mitochondria can be evaluated by monitoring the quenching of Calcein AM fluorescence. Specifically, 10 μl of Calcein AM (1000X) and 100 μl of chaotropic agent (100X) are added to 10 ml of detection buffer and mixed. Then take 1 ml of the above detection buffer and add 10 μl of cobalt chloride (100X) to 1 ml of detection buffer. As Figure 6 As shown in G, the fluorescence intensity of the EMCN+US group was the lowest, indicating that the opening degree of mPTP was the highest. The inventors also evaluated the expression of MCU. Figure 6 As shown in Figure H, the green fluorescence intensity representing MCU was weak in the control, ultrasound-only, and PPN-3 groups, indicating relatively low MCU expression levels. In contrast, cells treated with EMCN + US emitted the most pronounced green fluorescence. These results demonstrate that the KLAKLAK sequence depolarizes the mitochondrial membrane and opens MCU and mPTP channels, which mediate calcium uptake.
[0092] The intracellular calcium level was assessed using the fluorescent calcium probe Fluo-8 AM (see Figure 6 I). This experiment was divided into six groups: control group, ultrasound group, PPN-2 group, EMCN group, PPN-2 + ultrasound group, and ENCN + ultrasound group. PPN-2, PPN-3, or EMCN were all 20 μM in 1 ml of ultrasound. Ultrasound parameters were 1 MHz, 1.0 W / cm 2 , 50% duty cycle, 4 minutes of irradiation. Without ultrasound irradiation, cells exhibited a relatively weak green fluorescence signal related to calcium ions. However, after treatment with PPN-2+US and EMCN+US, a significantly enhanced green fluorescence signal was observed. The fluorescence intensity of cells in the EMCN+US group was brighter than that in the PPN-2+US group, due to greater damage to the endoplasmic reticulum after EMCN+US treatment.
[0093] In addition, to determine the mitochondrial Ca 2+ The fluorescent dye Rhod-2 / AM was used to detect mitochondrial Ca 2+ .like Figure 6 As shown in J, the EMCN+US group showed a stronger red fluorescence intensity than the other groups, because after the cells were treated with EMCN under ultrasound irradiation, Ca was released from the endoplasmic reticulum into the cytoplasm. 2+ Therefore, compared with PPN-3, EMCN plays a more important role in mitochondrial Ca uptake. 2+ The impact is more obvious.
[0094] The above shows that nanoparticles with KLAKLAK sequence open the Ca 2+ uptake channels, leading to cytoplasmic Ca 2+ Enters the mitochondria.
[0095] Experiment 5: Effects of agonists on organelles
[0096] BCL-2, BAX, and cleaved caspase-3 were detected by Western blotting. The experiment was divided into four groups: G1 control group, G2 EMCN group, G3 PPN-3 + ultrasound group, and G4 EMCN + ultrasound group. PPN-3 or EMCN was 20 μM in 1 ml of solution, and the ultrasound parameters were 1 MHz, 1.0 W / cm 2 , 50% duty cycle, irradiation for 4 minutes. The experiment found that under ultrasound irradiation, BAX and cleaved caspase-3 were significantly upregulated in the EMCN+US group, while BCL-2 expression was the lowest ( Figure 6 K), indicating that EMCN can activate the typical mitochondria-related apoptosis pathway under ultrasound irradiation.
[0097] In order to visually demonstrate the status of mitochondria and endoplasmic reticulum after different treatments, biological transmission electron microscopy (Bio-TEM) was used for analysis. The experiment was divided into four groups: control group only, PPN-3+ultrasound group, PPN-2+ultrasound group, and EMCN+ultrasound group. Figure 6 As shown in Figure 1, compared with the normal endoplasmic reticulum and mitochondrial morphology in the control group, the endoplasmic reticulum structure of cells treated with PPN-3+US was significantly abnormal, the cells were swollen, and the mitochondria were only slightly swollen. In addition, the mitochondrial structure of cells treated with PPN-2+US was swollen, and the changes in the endoplasmic reticulum were not obvious. Notably, cells treated with EMCN+US showed obvious abnormal changes in both the endoplasmic reticulum and mitochondrial structure, including significant swelling of the endoplasmic reticulum and swelling of the mitochondria. Overall, this dual mechanism highlights EMCN as a powerful strategy to enhance anti-tumor efficacy, acting through multi-organelle strikes ( Figure 6 (as shown in A).
[0098] Experiment 6: Verification of EMCN's in vitro anti-tumor efficacy and immune response
[0099] To investigate the anti-tumor effects of the agonists, the CCK8 assay was used to assess the survival rate of 4T1 cells after different treatments. The experiment was divided into six groups: G1: control group; G2: ultrasound alone; G3: Ce6 + ultrasound; G4: PPN-3 + ultrasound; G5: PPN-2 + ultrasound; and G6: EMCN + ultrasound. PPN-2, PPN-3, or EMCN were all 20 μM, and the dosage was 1 ml. The ultrasound parameters were 1 MHz, 1.0 W / cm 2 , 50% duty cycle, irradiation for 4 minutes. Compared with other groups, the experiment found that the cell survival rate of the EMCN+US group was the lowest and significantly decreased to below 30% ( Figure 7 A), which is attributed to the combined treatment of mitochondrial calcium overload apoptosis and endoplasmic reticulum stress mediated by EMCN under ultrasound irradiation.
[0100] Flow cytometry analysis also showed that the apoptosis rate of 4T1 cells in the EMCN+US group was significantly higher than that in other groups (see Figure 7 B. Figure 7 C), indicating that this method has a better therapeutic effect.
[0101] The therapeutic effects of different treatments were further evaluated by calcein AM / PI staining. Compared with other treatment groups, the EMCN+US group had the most dead cells ( Figure 7 E) These findings further suggest that a mutually reinforcing cycle between mitochondrial dysfunction and ER stress significantly accelerates apoptosis.
[0102] Lipid peroxidation (LPO) as a well-recognized biomarker of oxidative stress was evaluated using BODIPY-C11, a probe sensitive to LPO. Figure 7 Confocal laser scanning microscopy (CLSM) images in panel D show that a slight green fluorescence was observed in Ce6+US group compared to the control group, which was attributed to sonodynamic therapy-mediated oxidative stress. Cells treated with PPN-3+US and PPN-2+US exhibited moderate intensity of green fluorescence. Notably, cells treated with EMCN+US showed stronger green fluorescence than other groups. These findings suggest that the synergistic effect between endoplasmic reticulum stress and mitochondrial calcium apoptosis significantly enhanced oxidative stress.
[0103] To confirm the immunogenic cell death (ICD) effect of EMCN, the expression of calreticulin (CRT) on the cell surface and the release of high mobility group box 1 protein B1 (HMGB1), which are characteristic markers of ICD, were evaluated in 4T1 tumor cells after EMCN+US treatment. Confocal laser scanning microscopy (CLSM) images show that green fluorescence appeared on the plasma membrane of cells treated with PPN-3 and PPN-2 under ultrasound irradiation compared to the control group. Notably, the green fluorescence intensity of cells treated with EMCN+ultrasound was the strongest Figure 8 F). At the same time, the release of high mobility group box 1 protein B1 (HMGB1) was evaluated by detecting the decrease of green fluorescent spots in the nucleus after treatment. It was found that the release of HMGB1 from the nucleus to the extracellular environment induced by EMCN+ultrasound was the most significant compared to other groups Figure 7 G). In addition, the inventors also detected the ATP content of 4T1 cells under different treatment conditions and found that the intracellular ATP content of the EMCN+ultrasound group was also the lowest.
[0104] Previous studies have shown that mitochondrial dysfunction can make mitochondrial DNA (mtDNA) vulnerable to attack by reactive oxygen species (mtROS) produced by mitochondria, thereby promoting its leakage into the cytoplasm. This feature makes mtDNA a key target for mitochondria to participate in innate immune regulation. To evaluate the effect of EMCN+US on mitochondrial DNA leakage, the fluorescence of 8-hydroxydeoxyguanosine (8-OH-dG), a major product of DNA oxidation, was observed by confocal laser scanning microscopy (CLSM). As shown in Figure 7 H, the 8-OH-dG fluorescence intensity of the EMCN+US group was the strongest among all groups, which confirmed the escape of oxidatively damaged mitochondrial DNA (ox-mtDNA) from mitochondria to the cytoplasm.
[0105] The above results show that EMCN-induced endoplasmic reticulum stress and endogenous calcium apoptosis lead to the synergistic collapse of double organelles, thereby triggering a strong immune cell death (ICD) response, making it the most effective ICD inducer.
[0106] In addition, the performance of EMCN in inducing the maturation of dendritic cells (DCs) in vitro was detected by a Transwell system Figure 7 I). We found that EMCN+US treatment promoted the maturation of dendritic cells (DCs), with the proportion of mature DCs reaching up to 32.5% Figure 7 J), and the levels of pro-inflammatory factors (IL-6 and TNF-a) also increased Figure 7 O, Figure 7 P), indicating that synergistic organelle collapse enhanced the maturation of DCs and triggered a strong immune response.
[0107] When calcium in the endoplasmic reticulum is depleted, SOCE will be activated, allowing extracellular Ca 2+ to flow in to replenish the depleted Ca 2+ . Studies have shown that this process can induce the reprogramming of tumor-associated macrophages (TAMs), thereby reshaping the tumor microenvironment to create a more favorable environment for immune response. We studied the effect of endogenous calcium apoptosis on the phenotypic transformation of TAMs. As shown in Figure 7 L- Figure 7 N, we found that M1 macrophages were significantly increased and M2 macrophages were significantly decreased in the EMCN+US group. In addition, enzyme-linked immunosorbent assay (ELISA) was also used to analyze the secretion of IL-10 (M2 macrophage marker) and IL-12 (M1 macrophage marker) in the cell supernatant. The EMCN+US group showed significantly higher levels of IL-12 and significantly lower levels of IL-10 Figure 7 Q, Figure 7 R), indicating that EMCN+US treatment can polarize M2 macrophages to M1 macrophages.
[0108] Experiment 7: In vivo biodistribution and PAI imaging of EMCN nanostimulators
[0109] Through Experiment 6, EMCN nanostimulators showed significant anti-tumor effects and immune activation in vitro, which prompted us to further evaluate their therapeutic effects in vivo.
[0110] To observe the biodistribution and tumor aggregation behavior of EMCN, DIR-labeled nanostimulators were injected (3 μmol / kg) into 4T1 tumor-bearing mice via the tail vein, and further evaluated by a fluorescence imaging system. As shown in Figure 8As shown in Figure A, the fluorescence intensity in the tumor increased over time and reached a peak at 48 hours after injection. The corresponding tumor fluorescence recorded within 72 hours after injection showed that there was almost no enhancement in fluorescence intensity after the 48-hour time point Figure 8 B). Therefore, 48 hours after injection is the best time point for treatment.
[0111] In addition, mice were sacrificed to collect major organs and tumor tissues for in vitro bioimaging analysis. As shown in Figure Figure 8 C, Figure 8 D, due to the phagocytosis of the reticuloendothelial system (RES), EMCN has relatively high accumulation in major organs such as liver and spleen. At the same time, EMCN also shows strong tumor aggregation ability, which further confirms the tumor-targeted aggregation ability of EMCN and provides a strong guarantee for its good effect in tumor treatment.
[0112] Due to the excellent near-infrared absorption properties of Ce6, it has been widely used in photoacoustic imaging. Therefore, we believe that EMCN with Ce6 also has potential in photoacoustic imaging. After full-spectrum scanning of EMCN in a photoacoustic imaging instrument, 685 nm was determined as the optimal excitation wavelength for EMCN Figure 8 F). In vitro photoacoustic imaging showed that the photoacoustic intensity gradually increased with the increase of EMCN concentration, and showed a good linear relationship (R2=0.9815) Figure 8 E). In addition, the in vivo photoacoustic imaging ability of EMCN was also verified by 4T1 tumor-bearing mice. As shown in Figures Figure 8 H and Figure 8 G, after injection of EMCN into the tail vein, the photoacoustic intensity at the tumor site gradually increased over time and reached a peak at 48 hours. These findings indicate that EMCN has good photoacoustic imaging ability and can provide visual guidance for ultrasound irradiation during tumor treatment.
[0113] In order to observe the pharmacokinetic behavior of EMCN in vivo, DiR-labeled nanostimulants were injected into mice through the tail vein. Subsequently, blood samples were collected at different time points and the fluorescence intensity was detected by a fluorescence imaging system. The fluorescence intensity of the blood samples gradually decreased over time Figure 8 I), and the blood circulation half-life of EMCN was 9.26 hours Figure 8 J). This is a relatively long circulation time in the blood, which provides the possibility for enhancing tumor uptake of drugs and prolonging the treatment window of drugs.
[0114] Experiment 8: In vivo anti-tumor evaluation experiment of EMCN
[0115] Before the therapeutic experiment on 4T1 tumor-bearing mice, the biocompatibility and biosafety of EMCN were evaluated. Healthy mice were intravenously injected with EMCN (3 pmol / kg) at day 1, 3, 7, 14 and 28, respectively, and the control group was injected with normal saline. The blood and major organs of mice were collected. Compared with the control group, the mice injected with EMCN at different time points showed no significant difference in routine blood and blood biochemical analysis. In addition, hematoxylin-eosin (H&E) staining was performed on major organs (heart, liver, spleen, lung and kidney), and the results showed that there were no histopathological changes or abnormal inflammatory reactions in the short-term and long-term groups, which were not different from the control group. These results indicated that EMCN had good biocompatibility in vivo.
[0116] Subsequently, the anti-tumor effect of nanostimulants in 4T1 tumor-bearing mice was further evaluated. 4T1 tumor-bearing mice were randomly divided into six groups, and the tumor size and body weight of mice were recorded every two days Figure 9 A). As shown in Figure 9 B, the tumor growth of the control group and the ultrasound treatment group alone was rapid. The tumor inhibition rate of the Ce6+US group was 29.06±7.65%, while the tumor growth of the PPN-3+US group and the PPN-2+US group was relatively mild, with inhibition rates of 47.02±4.52% and 53.44±6.77%, respectively. In addition, the tumor inhibition rate of the EMCN+US group of mice was the highest, which was 80.56±5.61%. The tumor volume growth curve also showed that the tumor growth rate of the EMCN+US group was significantly slower than that of other groups Figure 9 F).
[0117] Subsequently, H&E staining, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining and proliferating cell nuclear antigen (PCNA) staining were performed. Compared with other groups, the tumor cell apoptosis rate of the EMCN+US group was the highest, and the proportion of proliferating cells was the lowest Figure 9 G). These results indicated that EMCN+US performed better in inhibiting tumor growth in vivo.
[0118] In addition, the ability of nanostimulants to produce reactive oxygen species (ROS) in tumor tissue under ultrasound irradiation was also evaluated by dihydroethidium (DHE) fluorescent staining. The strongest red fluorescence was detected in the EMCN+US group after intravenous injection for 48 hours and ultrasound irradiation of tumor tissue, which confirmed that EMCN could produce a large amount of reactive oxygen in situ in vivo.
[0119] Subsequently, proteomic analysis was used to identify and quantitatively evaluate the regulated receptor proteins on a large scale, thereby further exploring the anti-tumor mechanism of the nanoagonist. First, the principal component analysis (PCA) results showed that there was a clear separation between different sample groups, while samples within the same group showed good clustering, which fully demonstrated that there were significant differences in the translation level between the EMCN+US group and the control group ( Figure 9 H). The volcano plot showed that there were 820 differentially expressed proteins between the two groups, of which 451 proteins were upregulated and 369 proteins were downregulated after treatment with EMCN+US ( Figure 9 J). In addition, the heat map cluster analysis showed that the combination Figure 9 As shown in K, proteins such as Casp12, Ppp1r, and Map3k4, which are major indicators of caspase-dependent apoptosis, were significantly expressed in the EMCN+US group.
[0120] To better understand the biological functions of differentially expressed proteins induced by EMCN+US treatment, the inventors constructed a bubble map of proteins enriched in the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. Figure 9 As shown in Figure 1, the results showed that the differentially expressed proteins were mainly enriched in subcellular-related pathways, including endoplasmic reticulum-related processes, tricarboxylic acid (TCA) cycle, and oxidative phosphorylation.
[0121] Marker proteins in tumor tissues were detected by Western blotting. Figure 9 L- Figure 9 M, Compared with the control group, ultrasound alone group, and Ce6+ultrasound group, the major endoplasmic reticulum stress and mitochondrial calcium overload signaling proteins in tumor tissues were upregulated to the greatest extent after EMCN+ultrasound treatment.
[0122] Experiment 9: Validation of Nanoagonists Reshaping the Immunosuppressive Tumor Microenvironment ( Figure 10 A is a schematic diagram of the mechanism by which EMCN reshapes the immunosuppressive microenvironment)
[0123] Since the in vitro experimental results showed that nanoagonists can trigger a "damage-associated molecular pattern storm" through the coordinated collapse of dual organelles, thereby triggering a strong immune cell death effect and promoting the maturation of dendritic cells, immunofluorescence staining was performed to detect the exposure of calreticulin at the tumor site and the release of high-mobility group protein B1 from the cell nucleus to the intercellular space ( Figure 10 B. Figure 10C). Compared to the control group, Ce6+US, PPN-3+US, and PPN-2+US treatments induced, to some extent, calreticulin exposure and HMGB1 release from the nucleus to the intercellular space. Importantly, EMCN+US treatment induced the highest calreticulin exposure and HMGB1 release, indicating that ER stress and calcium-induced apoptosis can act synergistically to maximize the efficacy of immune cell death.
[0124] In addition, the ability of EMCN+US to induce systemic immune system resistance to tumors was further investigated. Therefore, the proportion of mature dendritic cells (CD80+, CD86+) in tumor-draining lymph nodes and tumors of mice in different treatment groups was detected by flow cytometry. The collected data showed that the proportion of mature dendritic cells in tumor-draining lymph nodes and tumors increased significantly after EMCN+US treatment. Specifically, compared with the control group, the proportion of mature dendritic cells in the lymph nodes ( Figure 10 D. Figure 10 E) was observed in the cervical follicles, and an increase of about 7.15 times was observed in the tumors ( Figure 10 F. Figure 10 J).
[0125] Subsequently, the inventors studied the ability of different treatments to re-educate tumor-associated macrophages (TAMs). Compared with the other groups, the percentage of M1 TAMs in the tumors of the EMCN+US treatment group was significantly increased, while the percentage of M2 TAMs was significantly decreased ( Figure 10 G. Figure 10 H and Figure 10 K). Meanwhile, the percentage of CD3+CD8+T cells was the highest in the EMCN+US group (39.98±2.27%), indicating that it has a stronger ability to promote the infiltration of cytotoxic T lymphocytes (CTLs) ( Figure 10 I. Figure 10 L). Compared with the other groups, the levels of cytokines IFN-γ, TNF-α, and IL-6 in the peripheral blood of the EMCN+US group were significantly increased, indicating that EMCN+US treatment has a strong immune response ( Figure 11 These results indicate that EMCN+US treatment can synergistically enhance immune cell death (ICD), stimulate dendritic cell (DCs) activation, promote tumor-specific cytotoxic T lymphocyte (CTLs) infiltration, and repolarize immunosuppressive macrophages to an immunostimulatory phenotype, thereby reversing the immunosuppressive tumor microenvironment (TME) and enhancing effective tumor-killing immunity ( Figure 10 A).
[0126] In addition, 4T1 tumor cells were injected into the tail vein (1×10 6A lung metastasis model was established by using 200 μl of cell suspension (using 100 cells per well) to further verify the effects of different treatments on inhibiting tumor metastasis. Figure 10 (Figure 5) Bouin staining and H&E staining of the lungs revealed that the control group and the US-only treatment group were still filled with metastatic nodules. Compared with the other treatment groups, the EMCN+US group had the fewest lung nodules, demonstrating a significant inhibitory effect on tumor metastasis, indicating that EMCN has excellent anti-tumor metastasis ability under ultrasound irradiation.
Claims
1. An endoplasmic reticulum targeting peptide comprising a KKKAA peptide sequence, characterized in that: The KKKAA peptide sequence is linked to the dihydrochlorin e6 and R8 peptides.
2. The endoplasmic reticulum targeting peptide according to claim 1, characterized in that: The dihydrochlorin e6 is linked to the amino group on the side chain of the first lysine in the KKKAA peptide sequence via a covalent bond.
3. The endoplasmic reticulum targeting peptide according to claim 1, wherein: The R8 peptide is linked to the α-amino group of the first lysine in the KKKAA peptide sequence via a peptide bond.
4. Agonist, characterized in that: The invention comprises the endoplasmic reticulum targeting peptide according to any one of claims 1 to 3, further comprising a mitochondrial membrane disrupting sequence and a sequence responsive to cathepsin B, wherein the mitochondrial membrane disrupting sequence is (KLAKLAK) 2, and the sequence responsive to cathepsin B is GFLG, and the mitochondrial membrane disrupting sequence is connected to the R8 peptide via the sequence responsive to cathepsin B.
5. A method for preparing an agonist, characterized in that: First, synthesize the endoplasmic reticulum targeting peptide according to any one of claims 1 to 3; Then, the cathepsin B-responsive sequence GFLG was used to connect the ER targeting peptide and the mitochondrial membrane disrupting sequence; The mitochondrial membrane disrupting sequence is (KLAKLAK)2.
6. A method for preparing an agonist, characterized in that: The following steps are involved: S1. EMCN polypeptide was synthesized using standard solid-phase peptide synthesis technology. The EMCN polypeptide sequence was (KLAKLAK)2GFLGR8KKKAA; S2. Incubating the obtained EMCN polypeptide in DMF containing hydrazine hydrate; then, sequentially adding HOBT, HBTU, and DIEA to the reaction system, using DMF as the solvent; S3. Subsequently, dihydrochlorin e6 is added to the above peptide chain and reacted in the dark; after the reaction is completed, the resin is washed with ethanol and dried under vacuum; S4. Subsequently, the product was cleaved from the resin using TFA to obtain a crude product; The crude product was precipitated from ice-cold ether and collected by centrifugation.
7. Use of the endoplasmic reticulum targeting peptide according to any one of claims 1 to 3 in the manufacture of a drug having an endoplasmic reticulum stress effect.
8. Use of the agonist according to claim 4 in the manufacture of a drug having the function of introducing calcium ions in the endoplasmic reticulum into mitochondria to cause endogenous calcium overload.
9. Use of the agonist according to claim 4 in the manufacture of an ICD inducer.
10. Use of the agonist according to claim 4 in the manufacture of a photoacoustic imaging agent.
Citation Information
Patent Citations
Process for producing cyanoalkylsilanes
US2906765A
Photochemically stable deep ultraviolet pellicles for excimer lasers
US5344677A
